JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A3004 Vemurafenib (PLX4032, RG7204)
9 Citation

Target: Raf

Summary: BRAF kinase inhibitor

≥24.5 mg/mL
A3009 Sorafenib
2 Citation

Target: Raf|VEGFR

Summary: Raf kinases and tyrosine kinases inhibitor

≥23.25 mg/mL
A3016 PLX-4720
1 Citation

Target: Raf

Summary: BRAF kinase inhibitor

≥20.69 mg/mL
A3018 Trametinib (GSK1120212)
7 Citation

Target: MEK

Summary: MEK1 and MEK2 inhibitor, potent and selective

insoluble in H2O; insoluble in EtOH; ≥15.38 mg/mL
A3347 Dabrafenib Mesylate (GSK-2118436)

Target: Raf

Summary: Inhibitor of BRAF(V600) mutants

≥30.75 mg/mL
A3887 Trametinib DMSO solvate
1 Citation

Target: MEK

Summary: Allosteric MEK1/MEK2 kinase inhibitor

insoluble in EtOH; insoluble in H2O; ≥11.2 mg/mL
A3943 XMD8-92

Target: ERK

Summary: BMK1/ERK5 inhibitor

≥23.75 mg/mL
A8226 TAK-632

Target: Raf

Summary: Pan-RAF inhibitor,potent and selective

≥27.75 mg/mL
A8245 Sorafenib Tosylate
1 Citation

Target: Raf|VEGFR

Summary: Raf kinases and tyrosine kinases inhibitor

≥31.85 mg/mL
A4604 SP 600125
7 Citation

Target: JNK

Summary: JNK1/2/3 inhibitor

insoluble in H2O; ≥11 mg/mL